Multiomics approaches to search for molecular-genetic predictors of osteoporosis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The identification of genetic loci and biochemical markers associated with the risk of fractures and the level of bone mineral density (BMD) did not give an unambiguous answer about the molecular pathogenesis of osteoporosis (OP). There are still unresolved questions about the possibility of early diagnosis and prognosis of the course of the disease. The molecular effects of genetic variants located in the coding regions of the human genome are easy to study. However, most of the single nucleotide polymorphic loci that are associated with osteoporosis susceptibility are located in non-coding or intergenic regions. Their role in the pathogenesis of this disease is not fully understood. The use of biochemical markers in the diagnosis and monitoring of osteoporosis therapy does not allow developing approaches to early diagnosis of the disease before a fracture occurs. Significant problems arise in the interpretation of research results for use in clinical medicine. But the combination of multidisciplinary data, such as genome-wide association study (GWAS), changes in the patterns of biogenic elements of bone remodeling, catalytic activity of a number of enzymes, and protein expression has significantly expanded the understanding of the key links in the pathogenesis of the disease. The article reviews and summarizes the latest advances in multiomics studies of osteoporosis, including bionformatic analysis to find key risk factors for the development of OP, as well as pharmacogenetic aspects of modern therapy of the disease.

Full Text

Restricted Access

About the authors

B. I Yalaev

Institute of Biochemistry and Genetics of the Ufa Federal Research Center of the Russian Academy of the Sciences

Email: yalaev.bulat@yandex.ru

A. V Tyurin

Bashkir State Medical University

R. I Khusainova

Institute of Biochemistry and Genetics of the Ufa Federal Research Center of the Russian Academy of the Sciences; Bashkir State Medical University

References

  1. Хусаинова, Р.И., Хуснутдинова Э.К. Генетика остеопороза. Уфа: Гилем; 2015.
  2. Ralston S.H., Uitterlinden A.G. Genetics of osteoporosis. Endocrine Reviews 2010; 31(5): 629-62.
  3. Kiel D.P., Demissie S.J., Dupuis K.L. et al. Genome-wide association with bone mass and geometry in the framingham heart study. BMC Medical Genetics 2007; 8(1): 14.
  4. Styrkarsdottir U., Halldorsson B.V., Gretarsdottir S. et al. Multiple genetic loci for bone mineral density and fractures. The New England Journal of Medicine 2008; 358(22): 2355-65.
  5. Richards J.B., Rivadeneira F., Inouye M. et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008; 371(9623): 1505-12.
  6. Rivadeneira F., Styrkarsdottir U., Estrada K. et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nature Genetics 2009; 41(11): 1199-206.
  7. Zheng H.F., Spector T.D., Richards J.B. Insights into the genetics of osteoporosis from recent genome-wide association studies. Expert Reviews in Molecular Medicine 2011; 13: 28.
  8. Vasikaran S.D., Glendenning P., Morris H.A. The Role of Biochemical Markers of Bone Turnover in Osteoporosis Management in Clinical Practice. Clinical Biochemist Reviews 2006; 27(3): 119-21.
  9. Seibel M.J. Biochemical Markers of Bone Turnover Part II: Clinical Applications in the Management of Osteoporosis. Clinical Biochemist Reviews 2006; 27(3): 123-38.
  10. Riggs B.L., Melton L.J., O’Fallon W.M. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996; 18(3): S197-201.
  11. Kuo T.R., Chen C.H. Bone biomarker for the clinical assessment of osteoporosis: Recent developments and future perspectives. Biomarker Research 2017; 5(1): 1-9.
  12. Karasik D., Rivadeneira F., Johnson M.L. The genetics of bone mass and susceptibility to bone diseases. Nature Reviews Rheumatology 2016; 12(6): 323-34.
  13. Makovey J., Nguyen T., Naganathan V. et al. Genetic effects on bone loss in periand postmenopausal women: A longitudinal twin study. Journal of Bone and Mineral Research 2007; 22(11): 1773-80.
  14. Howard G.M., Nguyen T.V., Harris M. et al. Genetic and environmental contributions to the association between quantitative ultrasound and bone mineral density measurements: A twin study. Journal of Bone and Mineral Research 1998; 13(8): 1318-27.
  15. Kitsios G.D., Zintzaras E. Genome-Wide Association Studies: hypothesis-free’ or ‘engaged’? Translational Research 2009; 154(4): 161-4.
  16. Estrada K., Styrkarsdottir U., Evangelou E. et al. Genome-wide metaanalysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics 2012; 44(5): 491-501.
  17. Clark G.R., Duncan E.L. The genetics of osteoporosis. British Medical Bulletin 2015; 113(1): 73-81.
  18. Deng F.Y. Is GSN significant for hip BMD in female Caucasians? Bone 2014; 63: 69-75.
  19. Xie P., Zhang L., Chen R. et al. Association of COL1A1 polymorphisms with osteoporosis: a meta-analysis of clinical studies. International Journal of Clinical and Experimental Medicine 2015; 8(9): 4764-81.
  20. Dytfeld J., Marcinkowska M., Drweska-Matelska N. et al. Association analysis of the COL1A1 polymorphism with bone mineral density and prevalent fractures in Polish postmenopausal women with osteoporosis. Archives of Medical Science 2016; 12(2): 288-94.
  21. Luo L., Xia W., Nie M. et al. Association of ESR1 and C6orf97 gene polymorphism with osteoporosis in postmenopausal women. Molecular Biology Reports 2014; 41(5): 3235-43.
  22. Zheng J., Frysz M., Kemp J.P. et al. Use of Mendelian Randomization to Examine Causal Inference in Osteoporosis. Frontiers in Endocrinology 2019; 10: 807.
  23. Trajanoska K., Rivadeneira F. Using Mendelian Randomization to Decipher Mechanisms of Bone Disease. Current Osteoporosis Reports 2018; 16(5): 531-40.
  24. Trajanoska K., Morris J.A., Oei L. et al. Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study. British Medical Journal 2018; 362: k3225.
  25. Cousminer D.L., Mitchell J.A., Chesi A. et al. Genetically determined later puberty impacts lowered bone mineral density in childhood and adulthood. Journal of Bone and Mineral Research 2018; 33(3): 430-6.
  26. Kemp J.P., Sayers A., Smith G.D. et al. Using Mendelian randomization to investigate a possible causal relationship between adiposity and increased bone mineral density at different skeletal sites in children. International Journal of Epidemiology 2016; 45(5): 1560-72.
  27. Ahmad O.S., Leong A., Miller J.A. et al. A Mendelian Randomization Study of the Effect of Type-2 Diabetes and Glycemic Traits on Bone Mineral Density. Journal of Bone and Mineral Research 2017; 32(5): 1072-81.
  28. Gan W., Clarke R.J., Mahajan A. et al. Bone mineral density and risk of type 2 diabetes and coronary heart disease: A Mendelian randomization study. Welcome Open Research 2017; 2: 68.
  29. Yokomoto-Umakoshi M., Umakoshi H., Miyazawa T. et al. Investigating the causal effect of fibroblast growth factor 23 on osteoporosis and cardiomet-abolic disorders: A Mendelian randomization study. Bone 2021; 143: 115777.
  30. Garnero P., Delmas P.D. New developments in biochemical markers for osteoporosis. Calcified Tissue International 1996; 59(1): S2-9.
  31. Deng F.Y., Liu Y.Z., Li M.L. et al. Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density. Proteomics 2008; 8(20): 4259-72.
  32. Deng F.Y., Lei S.F., Chen X.D. et al. An integrative study ascertained SOD2 as a susceptibility gene for osteoporosis in Chinese. Journal of Bone and Mineral Research 2011; 26(11): 2695-701.
  33. Qi T., Qu Q., Li G. et al. Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer. American Journal of Cancer Research 2020; 10(10): 3083-105.
  34. You Y.S., Lin Y.C., Liang H.J. et al. Association between the metabo-lome and low bone mineral density in taiwanese women determined by 1H NMR spectroscopy. Journal of Bone and Mineral Research 2014; 29(1): 212-22.
  35. Lello L., Raben T.G., Yong S.Y. et al. Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer. Scientific Reports 2019; 9(1): 15286.
  36. Moayyeri A., Cheung C.L., Tan K.C. et al. Metabolomic Pathways to Osteoporosis in Middle-Aged Women: A Genome-Metabolome-Wide Mendelian Randomization Study. Journal of Bone and Mineral Research 2018; 33(4): 643-50.
  37. Guo Y., Dong S.S., Chen X.F. et al. Integrating Epigenomic Elements and GWASs Identifies BDNF Gene Affecting Bone Mineral Density and Osteoporotic Fracture Risk. Scientific Reports 2016; 6: 1-12.
  38. Morris J.A., Kemp J.P., Youlten S.E. et al. An atlas of genetic influences on osteoporosis in humans and mice. Nature Genetics 2019; 51(2): 258-66.
  39. Chesi A., Wagley Y., Johnson M.E. et al. Genome-scale Capture C. promoter interactions implicate effector genes at GWAS loci for bone mineral density. Nature Communications 2019; 10(1): 1260.
  40. Chen X.F., Zhu D.L., Yang M. et al. An Osteoporosis Risk ОНП at 1p36.12 Acts as an Allele-Specific Enhancer to Modulate LINC00339 Expression via Long-Range Loop Formation. American Journal of Human Genetics 2018; 102(5): 776-93.
  41. Reppe S., Datta H., Gautvik K. The Influence of DNA Methylation on Bone Cells. Current Genomics 2015; 16(6): 384-92.
  42. Yalaev B.I., Tyurin A.V., Mirgalieva R.Y. et al. The role of DNA methylation in the disorders of bone metabolism. Vavilov journal of genetics and breeding 2019; 23(1): 67-74.
  43. Ялаев Б.И., Хусаинова Р.И. Эпигенетика остеопороза. Медицинская генетика 2018; 12(6): 3-10.
  44. Галицына Е.В., Бухарова Т.Б., Васильев А.В. и соавт. МикроРНК в регуляции остеогенеза in vitro и in vivo: от фундаментальных механизмов к патогенезу заболеваний костной ткани. Гены и клетки 2019; 14(1): 41-8.
  45. Zhang F., Wang D. The pattern of microRNA binding site distribution. Genes 2017; 8(11): 296.
  46. Chen J., Qiu M., Dou C. et al. MicroRNAs in Bone Balance and Osteoporosis. Drug Development Research 2015; 76(5): 235-45.
  47. Lei S.F., Papasian C.J., Deng H.W. Polymorphisms in predicted miRNA binding sites and osteoporosis. Journal of Bone and Mineral Research 2011; 26(1): 72-8.
  48. Гребенникова Т.А., Белая Ж.Е., Рожинская Л.Я. и соавт. Эпигенетические аспекты остеопороза. Вестник российской академии медицинских наук 2015; 70(5): 541-8.
  49. Cohen-Kfir E., Artsi H., Levin A. et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 2011; 152(12): 4514-24.
  50. Dydykina I.S., Vetkova E.S. Sclerostin and its role in the regulation of bone metabolism. Rheumatology Science and Practice 2013; 51(3): 296-301.
  51. Kim H.N., Lee J.H., Jin W.J. et al. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice. European Journal of Pharmacology 2012; 691(1-3): 69-76.
  52. Cosman F., Beur S.J., LeBoff M.S. et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis International 2014; 25(10): 2359-81.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies